<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Hepatol Int</journal-id><journal-id journal-id-type="iso-abbrev">Hepatol Int</journal-id><journal-title-group><journal-title>Hepatology International</journal-title></journal-title-group><issn pub-type="ppub">1936-0533</issn><issn pub-type="epub">1936-0541</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21773778</article-id><article-id pub-id-type="pmc">3314819</article-id><article-id pub-id-type="publisher-id">9294</article-id><article-id pub-id-type="doi">10.1007/s12072-011-9294-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Xie</surname><given-names>Wen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Guangfeng</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Hongfei</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Guiming</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Zujiang</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Lang</surname><given-names>Zhenwei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Hong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yan</surname><given-names>Jie</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Cheng</surname><given-names>Jun</given-names></name><address><email>jun.cheng.ditanhospital@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Liver Center, Beijing Ditan Hospital, Capital Medical University, 100015 Beijing, China </aff><aff id="Aff2"><label>2</label>Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China </aff><aff id="Aff3"><label>3</label>Department of Pediatric Hepatology, The 302 Hospital of PLA, Beijing, China </aff><aff id="Aff4"><label>4</label>Department of Hepatology, Tianjin Municipal Hospital of Infectious Diseases, Tianjin, China </aff><aff id="Aff5"><label>5</label>Department of Infectious Diseases, First Hospital, Zhengzhou University, Zhengzhou, China </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>7</month><year>2011</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>7</month><year>2011</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2012</year></pub-date><volume>6</volume><issue>2</issue><fpage>441</fpage><lpage>448</lpage><history><date date-type="received"><day>28</day><month>1</month><year>2011</year></date><date date-type="accepted"><day>20</day><month>6</month><year>2011</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2011</copyright-statement></permissions><abstract id="Abs1"><sec><title>Objective</title><p>To evaluate the efficacy and safety profiles of patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) treated with adefovir dipivoxil (ADV) or ADV plus bicyclol, and to optimize the treatment strategy for CHB patients.</p></sec><sec><title>Patients and methods</title><p>A total of 250 patients with HBeAg-positive CHB were randomized to ADV plus bicyclol combination group and ADV monotherapy group. The patients in the ADV plus bicyclol combination therapy group (<italic>n</italic>&#x000a0;=&#x000a0;125) received ADV 10&#x000a0;mg orally q.d. and bicyclol 25&#x000a0;mg orally t.i.d. for 48&#x000a0;weeks, and those in the ADV monotherapy group (<italic>n</italic>&#x000a0;=&#x000a0;125) were administered ADV 10&#x000a0;mg orally q.d. alone for 48&#x000a0;weeks. The serum aminotransferases (ALT/AST), HBV DNA, HBeAg/HBeAb, and liver biopsy were conducted before and after therapy.</p></sec><sec><title>Results</title><p>The serum aminotransferase levels were decreased significantly in both groups. The serum aminotransferase level in ADV plus bicyclol combination therapy group decreased greater than that in ADV monotherapy group (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01). The virological response rate in ADV plus bicyclol combination therapy group was not significantly different from that in ADV monotherapy group (<italic>P</italic>&#x000a0;&#x0003e;&#x000a0;0.05). After treatment for 48&#x000a0;weeks, the Knodell necroinflammatory score of the two groups were all alleviated significantly, and the Knodell score in the combination group was significantly lower than that in the ADV monotherapy group (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05). There were no remarkable adverse events probably related to the drug in this study.</p></sec><sec><title>Conclusion</title><p>Adefovir dipivoxil plus bicyclol combination therapy is a safe and superior treatment regimen for patients with HBeAg-positive CHB when compared with ADV monotherapy.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Chronic hepatitis B</kwd><kwd>Adefovir dipivoxil</kwd><kwd>Bicyclol</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Asian Pacific Association for the Study of the Liver 2012</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Chronic hepatitis B virus (HBV) infection is a major health problem worldwide [<xref ref-type="bibr" rid="CR1">1</xref>]. Carriers of HBV have increased risk of developing cirrhosis, liver decompensation, and hepatocellular carcinoma (HCC) [<xref ref-type="bibr" rid="CR2">2</xref>]. About 15&#x02013;40% of the HBV carriers will develop serious liver diseases during their lifetime [<xref ref-type="bibr" rid="CR3">3</xref>]. The chronic hepatitis B (CHB) is becoming a worldwide burden because the pathologic mechanism is complex and it is difficult to eradicate the HBV completely [<xref ref-type="bibr" rid="CR4">4</xref>]. Effective treatments are required to prevent progression of CHB to cirrhosis, HCC, and death [<xref ref-type="bibr" rid="CR5">5</xref>]. Monotherapy using interferon (IFN) or nucleos(t)ide (NUC) analogs has strong clinical evidence [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. But only a small percentage of HBeAg-positive CHB patients experienced HBeAg loss or seroconversion after 1&#x000a0;year therapy with IFN/pegylated IFN. Short-term treatment of CHB patients with NUC is insufficient and prolonged therapy may result in high cost and drug resistance [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. The notion of combination therapy for CHB treatment has been previously examined, yielding inconclusive results [<xref ref-type="bibr" rid="CR10">10</xref>]. It is an urgent task to have better strategies for the future treatment of patients with CHB.</p><p>The final goal of antiviral therapy for patients with CHB is to reduce the incidence of end-stage liver diseases, and increase the chance of living a longer, better life [<xref ref-type="bibr" rid="CR11">11</xref>]. For this purpose, the recent goal was to improve the liver histology with either IFN/PEG&#x02013;IFN or NUC [<xref ref-type="bibr" rid="CR12">12</xref>]. Antiviral therapy with either IFN/PEG-IFN or NUC has shown only a partial improvement in liver histology [<xref ref-type="bibr" rid="CR13">13</xref>]. Adefovir dipivoxil (ADV) is an oral prodrug of adefovir, an analog of adenosine monophosphate, widely used in the clinical treatment of CHB patients [<xref ref-type="bibr" rid="CR14">14</xref>]. The active intracellular metabolite, adefovir diphosphate, inhibits HBV DNA polymerase at levels much lower than those needed to inhibit the human DNA polymerases [<xref ref-type="bibr" rid="CR15">15</xref>]. Studies in vivo and in vitro showed that adefovir could significantly inhibit the replication of HBV DNA in both wild type and YMDD mutant type [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p>For hepatologists, especially in East Asian countries, liver protectant drug played an important role in the treatment of CHB patients for a long time before antiviral therapy was made available [<xref ref-type="bibr" rid="CR17">17</xref>]. Accumulated clinical evidence demonstrated significant histological improvement after the liver protectant drug therapy [<xref ref-type="bibr" rid="CR18">18</xref>]. Bicyclol is 4, 4&#x02032;-dimethoxy-5, 6, 5&#x02032;, 6&#x02032;-dimethylene-dioxy-2, 2&#x02032;-dicarboxylate biphenyl, a widely used liver protectant drug in China and other countries [<xref ref-type="bibr" rid="CR19">19</xref>]. Although the mechanism of action of bicyclol is largely unknown, its anti-liver injury, anti-liver inflammation, and anti-liver fibrosis effects have been well established in the recent years [<xref ref-type="bibr" rid="CR20">20</xref>]. Both experimental and clinical studies have shown that bicyclol can significantly reduce the experimental liver injury and liver fibrosis, and has significant antiinflammatory activity [<xref ref-type="bibr" rid="CR21">21</xref>]. The mechanism of action is closely related to the elimination of free radicals, protection of membrane and mitochondrial functions, suppression of oxidative damage, induction of vivo antioxidants, and inhibition of the serum TNF&#x003b1;, and inflammatory cytokines that were induced by chronic carbon tetrachloride injury [<xref ref-type="bibr" rid="CR22">22</xref>]. Recent studies indicate that bicyclol not only promotes Th1-type cytokine-mediated immune responses but also downregulates Th2-type cytokine-mediated immune responses [<xref ref-type="bibr" rid="CR23">23</xref>]. Bicyclol can reduce liver inflammation and protect liver from cell injury, decrease collagen synthesis and secretion, and promote the degradation and absorption of collagen. Therefore, it can inhibit the formation and development of liver fibrosis [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p>Pilot antiviral drug plus liver protectant drug have been proved to be effective for the treatment of CHB, but there is no well-designed clinical study conducted till now. To establish strong evidence for the antiviral plus liver protectant drug for CHB patients, we evaluated the efficacy and safety profiles by combining ADV with liver protectant drug (bicyclol) on HBeAg-positive CHB patients in China, and the results, especially the improvement in histology, are obviously promising.</p></sec><sec id="Sec2" sec-type="methods"><title>Patients and methods</title><sec id="Sec3"><title>Patient population</title><p>Altogether 250, including 182 male and 68 female patients with HBeAg-positive CHB were enrolled in this study. Average age of all patients was 35.4&#x000a0;years (18&#x02013;60&#x000a0;years), who had been diagnosed with CHB for &#x02265;6&#x000a0;months. All the patients were IFN/PEG&#x02013;IFN or NUC treatment naive. The baseline serum alanine aminotransferase (ALT) level was 2&#x02013;10 times of the upper limit of the normal (ULN) for all the patients. Serum HBsAg and HBV DNA continued to be positive for &#x0003e;6&#x000a0;months. All the patients were HBeAg-positive and -negative, with a serum HBV DNA level of &#x02265;1.0&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup> copies/mL, and none had concomitant other categories hepatitis virus infection. A total bilirubin level was &#x02264;3.0&#x000a0;mg/dL (50&#x000a0;&#x003bc;mol/L) and relatively stable recently. Simultaneously, drug-induced hepatitis, alcoholic hepatitis, and autoimmune hepatitis were excluded. A total of 250 patients were randomly assigned to ADV monotherapy and ADV plus bicyclol combination therapy groups.</p></sec><sec id="Sec4"><title>Therapeutic schedule</title><p>Patients in the monotherapy group were treated with 10&#x000a0;mg of ADV (Tianjin Institute of Pharmaceutical Research Pharmaceutical Company, Limited, Tianjin, China) (<italic>n</italic>&#x000a0;=&#x000a0;125), and patients in the combination therapy group with 10&#x000a0;mg of ADV plus 75&#x000a0;mg (25&#x000a0;mg, t.i.d.) of bicyclol (Beijing Union Pharmaceutical Factory, Beijing, China) (<italic>n</italic>&#x000a0;=&#x000a0;125) daily, both for 48&#x000a0;weeks.</p><p>Other antiviral drugs and liver protectant drugs were not allowed during the therapy.</p></sec><sec id="Sec5"><title>Liver biochemistry and serological markers of HBV</title><p>The serum biochemistry parameters, including ALT and AST, were determined every 12&#x000a0;weeks. HBV serological markers, including HBsAg, anti-HBs, HBeAg, and anti-HBeAg, were determined by a microparticle enzyme immunoassay. Reagents used in the determination of liver biochemistry and HBV serology were purchased from Abbott Laboratories (USA). Real-time PCR was performed to quantitatively detect the serum HBV DNA using the PG HBV FQ-PCR kit (Shenzhen PG Biotech). The lower limit detection of this system was 1,000&#x000a0;copies/ml.</p></sec><sec id="Sec6"><title>Liver pathological examination</title><sec id="Sec7"><title>Liver biopsy</title><p>Liver biopsy was performed using a16&#x000a0;G needle, requiring hepatic tissue &#x02265;1&#x000a0;cm, including four and more than four portal areas. Processing of the tissue and preparation of microscopic sections were performed conventionally. Thickness of the films was 4&#x000a0;&#x003bc;m, and they were stained by hematoxylin&#x02013;eosin, silver impregnation method, and Masson trichrome.</p></sec><sec id="Sec8"><title>Evaluation of liver histopathology</title><p>The pathological expert was blinded to all sections at baseline and 48&#x000a0;weeks of treatment for evaluating liver histology activity index (HAI), necroinflammation, and fibrosis scores according to the Knodell necroinflammatory score system [<xref ref-type="bibr" rid="CR25">25</xref>].</p></sec></sec><sec id="Sec9"><title>Statistical analysis</title><p>All analyses were performed using SPSS version 16.0 (SPSS Inc, USA). The demographics of patients and virological response were compared by the Student&#x02019;s <italic>t</italic> test for continuous data and Chi-square test for dichotomous data. A value of <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 was considered statistically significant.</p></sec><sec id="Sec10"><title>Ethical issue</title><p>A consent form was signed by each patient before enrollment to the study.</p></sec></sec><sec id="Sec11"><title>Results</title><p>Eight patients withdrew from the study during 48&#x000a0;weeks of treatment. Of the remaining 242 patients, 122 patients received 10&#x000a0;mg of ADV plus 75&#x000a0;mg of bicyclol daily (combination therapy group), and 122 patients received 10&#x000a0;mg of ADV alone (monotherapy group). There were no significant differences in the demographic or HBV disease characteristics between the two groups (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Comparison of baseline characteristics of patients in ADV monotherapy and ADV plus bicyclol combination therapy groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Combination therapy (<italic>n</italic>&#x000a0;=&#x000a0;125)</th><th align="left">Monotherapy (<italic>n</italic>&#x000a0;=&#x000a0;125)</th></tr></thead><tbody><tr><td align="left">Age</td><td align="left">35.2&#x000a0;&#x000b1;&#x000a0;10.2</td><td align="left">35.7&#x000a0;&#x000b1;&#x000a0;11.3</td></tr><tr><td align="left">BMI (kg/m<sup>2</sup>)</td><td align="left">21.5&#x000a0;&#x000b1;&#x000a0;2.8</td><td align="left">20.8&#x000a0;&#x000b1;&#x000a0;3.1</td></tr><tr><td align="left">Gender: female (%)</td><td align="left">33/125 (26.4)</td><td align="left">35/125 (28.0)</td></tr><tr><td align="left">Time since diagnosis &#x02265;2&#x000a0;years (%)</td><td align="left">61/125 (48.8)</td><td align="left">59/125 (47.2)</td></tr><tr><td align="left">HBV DNA, log<sub>10</sub> copies/mL</td><td align="left">7.0&#x000a0;&#x000b1;&#x000a0;1.3</td><td align="left">6.9&#x000a0;&#x000b1;&#x000a0;1.0</td></tr><tr><td align="left">ALT (U/L)</td><td align="left">153.4&#x000a0;&#x000b1;&#x000a0;68.8</td><td align="left">146.5&#x000a0;&#x000b1;&#x000a0;59.3</td></tr><tr><td align="left">ALT range (%)</td><td align="left" colspan="2"/></tr><tr><td align="left">&#x000a0;2 to &#x02264;5&#x000a0;&#x000d7;&#x000a0;ULN</td><td align="left">76/125 (60.8)</td><td align="left">75/125 (57.6)</td></tr><tr><td align="left">&#x000a0;&#x0003e;5&#x000a0;&#x000d7;&#x000a0;ULN</td><td align="left">49/125 (39.2)</td><td align="left">53/125 (42.4)</td></tr></tbody></table><table-wrap-foot><p>No significant differences were observed for age, BMI, gender, time since diagnosis, HBV DNA viral load, ALT levels of patients in ADV monotherapy compared with ADV plus bicyclol combination therapy groups</p></table-wrap-foot></table-wrap></p><sec id="Sec12"><title>Biochemical responses</title><p>Serum ALT levels of patients at 24 and 48&#x000a0;weeks of treatment in both ADV plus bicyclol combination therapy group (39.8&#x000a0;&#x000b1;&#x000a0;25.6 vs. 153.4&#x000a0;&#x000b1;&#x000a0;68.8; 30.3&#x000a0;&#x000b1;&#x000a0;14.1 vs. 153.4&#x000a0;&#x000b1;&#x000a0;68.8) and ADV monotherapy group (66.1&#x000a0;&#x000b1;&#x000a0;42.7 vs. 146.5&#x000a0;&#x000b1;&#x000a0;59.3; 46.4&#x000a0;&#x000b1;&#x000a0;30.3 vs. 146.5&#x000a0;&#x000b1;&#x000a0;59.3) were significantly decreased when compared with the baseline levels, respectively (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01,&#x000a0;&#x0003c;0.01). Serum AST levels of patients at 24 and 48&#x000a0;weeks of treatment in both ADV plus bicyclol combination therapy group (46.6&#x000a0;&#x000b1;&#x000a0;26.9 vs. 136.3&#x000a0;&#x000b1;&#x000a0;50.7; 40.8&#x000a0;&#x000b1;&#x000a0;20.2 vs. 136.3&#x000a0;&#x000b1;&#x000a0;50.7) and ADV monotherapy group (67.9&#x000a0;&#x000b1;&#x000a0;38.7 vs. 132.2&#x000a0;&#x000b1;&#x000a0;50.7; 48.2&#x000a0;&#x000b1;&#x000a0;27.5 vs. 132.2&#x000a0;&#x000b1;&#x000a0;50.7) were significantly decreased compared with baseline levels, respectively (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>) (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01). At the 24 and 48&#x000a0;weeks of therapy, both ALT and AST levels of patients in combination group (39.8&#x000a0;&#x000b1;&#x000a0;25.6 vs. 66.1&#x000a0;&#x000b1;&#x000a0;42.7; 30.3&#x000a0;&#x000b1;&#x000a0;14.1 vs. 46.4&#x000a0;&#x000b1;&#x000a0;30.3) were significantly lower than that of patients in the monotherapy group (46.6&#x000a0;&#x000b1;&#x000a0;26.9 vs. 67.9&#x000a0;&#x000b1;&#x000a0;38.7; 40.8&#x000a0;&#x000b1;&#x000a0;20.2 vs. 48.2&#x000a0;&#x000b1;&#x000a0;27.5), respectively (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>; Figs.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, <xref rid="Fig2" ref-type="fig">2</xref>) (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Dynamic changes of ALT and AST levels during treatment (<italic>x</italic>&#x000a0;&#x000b1;&#x000a0;<italic>s</italic>, U/L)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">No. (<italic>n</italic>)</th><th align="left">Baseline</th><th align="left">24&#x000a0;weeks</th><th align="left">48&#x000a0;weeks</th></tr></thead><tbody><tr><td align="left" colspan="5">ALT</td></tr><tr><td align="left">&#x000a0;Monotherapy</td><td align="left">120</td><td char="&#x000b1;" align="char">146.5&#x000a0;&#x000b1;&#x000a0;59.3</td><td char="&#x000b1;" align="char">66.1&#x000a0;&#x000b1;&#x000a0;42.7</td><td char="&#x000b1;" align="char">46.4&#x000a0;&#x000b1;&#x000a0;30.3</td></tr><tr><td align="left">&#x000a0;Combination</td><td align="left">122</td><td char="&#x000b1;" align="char">153.4&#x000a0;&#x000b1;&#x000a0;68.8</td><td char="&#x000b1;" align="char">39.8&#x000a0;&#x000b1;&#x000a0;25.6<sup>a</sup></td><td char="&#x000b1;" align="char">30.3&#x000a0;&#x000b1;&#x000a0;14.1<sup>a,b</sup></td></tr><tr><td align="left" colspan="5">AST</td></tr><tr><td align="left">&#x000a0;Monotherapy</td><td align="left">120</td><td char="&#x000b1;" align="char">133.2&#x000a0;&#x000b1;&#x000a0;50.7</td><td char="&#x000b1;" align="char">67.9&#x000a0;&#x000b1;&#x000a0;38.7</td><td char="&#x000b1;" align="char">48.2&#x000a0;&#x000b1;&#x000a0;27.5</td></tr><tr><td align="left">&#x000a0;Combination</td><td align="left">122</td><td char="&#x000b1;" align="char">136.3&#x000a0;&#x000b1;&#x000a0;50.7</td><td char="&#x000b1;" align="char">46.6&#x000a0;&#x000b1;&#x000a0;26.9<sup>a</sup></td><td char="&#x000b1;" align="char">40.8&#x000a0;&#x000b1;&#x000a0;20.2<sup>a,b</sup></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Compared to baseline level, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01</p><p><sup>b</sup>Compared to ADV monotherapy group, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Baseline average ALT level for patients in ADV monotherapy group is not significantly different to that of ADV plus bicyclol combination therapy group. At weeks 24 and 48 of treatment, ALT levels were significantly decreased for patients in both groups compared with that of baseline levels (*<italic>P</italic>&#x000a0;<italic>&#x0003c;</italic>&#x000a0;0.01), ALT levels decreased more significantly in combination therapy group than that in monotherapy group, respectively (<sup>#</sup><italic>P</italic>&#x000a0;<italic>&#x0003c;</italic>&#x000a0;0.01)</p></caption><graphic xlink:href="12072_2011_9294_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Baseline average AST level for patients in ADV monotherapy group is not significantly different to that of ADV plus bicyclol combination therapy group. At weeks 24 and 48 of treatment, AST levels were significantly decreased for patients in both groups compared with that of baseline levels (*<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01), AST levels decreased more significantly in combination therapy group than that in monotherapy group, respectively (<sup>#</sup><italic>P</italic>&#x000a0;<italic>&#x0003c;</italic>&#x000a0;0.01)</p></caption><graphic xlink:href="12072_2011_9294_Fig2_HTML" id="MO2"/></fig></p><p>ALT normalization rates of patients in combination therapy group at 12, 24, 36, and 48&#x000a0;weeks(48.4, 64.8, 70.5, and 78.7%) were significantly higher than that of patients in monotherapy group (25.8, 42.5, 50.8, and 60.0%), respectively (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>; Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>) (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01). AST normalization rates of patients in combination therapy group at 12, 24, 36, and 48&#x000a0;weeks (44.3, 59.0, 63.9, and 68.7%) were significantly higher than that of patients in the monotherapy group (25.0, 40.0, 46.7, and 54.2%), respectively (for week 12, 24, and 36, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01; for week 48, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05) (Table <xref rid="Tab3" ref-type="table">3</xref>; Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Comparison of ALT, AST normalization rates in two groups during treatment and virological responses in two treatment groups at 48&#x000a0;weeks</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Group</th><th align="left" colspan="3">ALT normalization rates</th><th align="left" colspan="3">AST normalization rates</th><th align="left" colspan="3">Serological markers of HBV at 48&#x000a0;week</th></tr><tr><th align="left">12&#x000a0;week</th><th align="left">24&#x000a0;week</th><th align="left">48&#x000a0;week</th><th align="left">12&#x000a0;week</th><th align="left">24&#x000a0;week</th><th align="left">48&#x000a0;week</th><th align="left">HBV DNA &#x02264;&#x000a0;1,000 copies/mL</th><th align="left">HBeAg loss</th><th align="left">HBeAg seroconversion</th></tr></thead><tbody><tr><td align="left">Monotherapy % (<italic>n</italic>)</td><td align="left">25.8 (31/120)</td><td align="left">42.5 (51/120)</td><td align="left">60.0 (72/120)</td><td align="left">25.0 (30/120)</td><td align="left">40.0 (48/120)</td><td align="left">54.2 (65/120)</td><td align="left">31.7 (38/120)</td><td align="left">25.8 (31/120)</td><td align="left">18.3 (22/120)</td></tr><tr><td align="left">Combination % (<italic>n</italic>)</td><td align="left">48.4 (59/122)<sup>a</sup></td><td align="left">64.8 (79/122)<sup>a</sup></td><td align="left">78.7 (96/122)<sup>a</sup></td><td align="left">44.3 (54/122)<sup>a</sup></td><td align="left">59.0 (72/122)<sup>a</sup></td><td align="left">68.7 (83/122)<sup>b</sup></td><td align="left">34.4 (42/122)</td><td align="left">29.5 (36/122)</td><td align="left">20.5 (25/122)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Compared to ADV monotherapy group, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01</p><p><sup>b</sup><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05</p></table-wrap-foot></table-wrap><fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Rates of ALT normalization at the weeks 12, 24, 36, and 48 of the treatment in patients of ADV plus bicyclol combination therapy group were significantly higher than that in ADV monotherapy group, respectively (*<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01)</p></caption><graphic xlink:href="12072_2011_9294_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Rates of AST normalization at weeks 12, 24, and 36 of the treatment in patients of ADV plus bicyclol combination therapy group were significantly higher than that in ADV monotherapy group, respectively (*<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01). Rate of AST normalization at week 48 of the treatment in patients of ADV plus bicyclol combination therapy group is significantly higher than that in ADV monotherapy group (<sup>#</sup><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05)</p></caption><graphic xlink:href="12072_2011_9294_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec13"><title>Virological and immunological responses</title><p>At the end of treatment, the HBV DNA levels were found to be significantly decreased from 6.9&#x000a0;&#x000b1;&#x000a0;1.0 log<sub>10</sub> copies/mL at baseline to 3.1&#x000a0;&#x000b1;&#x000a0;1.2 log<sub>10</sub> copies/mL at week 48 for patients in the monotherapy group (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01), and from 7.0&#x000a0;&#x000b1;&#x000a0;1.0 to 3.3&#x000a0;&#x000b1;&#x000a0;1.2&#x000a0;log<sub>10</sub> copies/mL for patients in the combination therapy group (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01). The HBV DNA levels, however, had no significant difference between the monotherapy group (3.1&#x000a0;&#x000b1;&#x000a0;1.2 log<sub>10</sub> copies/mL) and the combination therapy group (3.3&#x000a0;&#x000b1;&#x000a0;1.2 log<sub>10</sub> copies/mL) at week 48 (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>) (<italic>P</italic>&#x000a0;&#x0003e;&#x000a0;0.05). At the end of treatment, percentages of patients with HBV DNA&#x000a0;&#x02264;1,000 log<sub>10</sub> copies/mL, HBeAg loss, and HBeAg seroconversion in monotherapy group (31.7, 25.8, and 18.3%, respectively) were not significantly different to that in the combination therapy group (34.4, 29.5, and 20.5%, respectively) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p></sec><sec id="Sec14"><title>Histological improvements</title><p>Liver biopsy was performed twice in 87 patients, at baseline and after treatment at week 48, with 45 patients in the ADV plus bicyclol combination therapy group and 42 patients in the ADV monotherapy group. Average Knodell necroinflammatory score was found to be significantly decreased from 7.0&#x000a0;&#x000b1;&#x000a0;3.0 at baseline to 4.6&#x000a0;&#x000b1;&#x000a0;2.8 at week 48 for patients in monotherapy group, and from 7.4&#x000a0;&#x000b1;&#x000a0;2.9 at baseline to 3.5&#x000a0;&#x000b1;&#x000a0;2.0 at week 48 for patients in combination therapy group (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01). After 48&#x000a0;weeks of treatment, Knodell necroinflammatory score reduction in combination therapy group was significantly greater than that in monotherapy group (3.8&#x000a0;&#x000b1;&#x000a0;2.9 vs. 2.4&#x000a0;&#x000b1;&#x000a0;2.3, respectively) (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>) (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05). <table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Comparison of Knodell necroinflammatory scores in two groups at 48&#x000a0;weeks of therapy</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Group</th><th align="left" colspan="3">Necroinflammatory scores (<italic>x</italic>&#x000a0;&#x000b1;&#x000a0;<italic>s</italic>)</th><th align="left" colspan="3">Fibrosis scores (<italic>x</italic>&#x000a0;&#x000b1;&#x000a0;<italic>s</italic>)</th></tr><tr><th align="left">Baseline</th><th align="left">At 48&#x000a0;weeks</th><th align="left">Reduction</th><th align="left">Baseline</th><th align="left">At 48&#x000a0;weeks</th><th align="left">Reduction</th></tr></thead><tbody><tr><td align="left">Monotherapy</td><td char="&#x000b1;" align="char">7.0&#x000a0;&#x000b1;&#x000a0;3.0</td><td char="&#x000b1;" align="char">4.6&#x000a0;&#x000b1;&#x000a0;2.8<sup>a</sup></td><td char="&#x000b1;" align="char">2.4&#x000a0;&#x000b1;&#x000a0;2.3</td><td char="&#x000b1;" align="char">1.6&#x000a0;&#x000b1;&#x000a0;0.91</td><td char="&#x000b1;" align="char">1.0&#x000a0;&#x000b1;&#x000a0;0.66</td><td char="&#x000b1;" align="char">0.5&#x000a0;&#x000b1;&#x000a0;0.2</td></tr><tr><td align="left">Combination therapy</td><td char="&#x000b1;" align="char">7.4&#x000a0;&#x000b1;&#x000a0;2.9</td><td char="&#x000b1;" align="char">3.5&#x000a0;&#x000b1;&#x000a0;2.0<sup>a</sup></td><td char="&#x000b1;" align="char">3.8&#x000a0;&#x000b1;&#x000a0;2.9<sup>b</sup></td><td char="&#x000b1;" align="char">2.0&#x000a0;&#x000b1;&#x000a0;1.0</td><td char="&#x000b1;" align="char">1.2&#x000a0;&#x000b1;&#x000a0;0.8</td><td char="&#x000b1;" align="char">0.7&#x000a0;&#x000b1;&#x000a0;0.3</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Compared to the baseline scores, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01</p><p><sup>b</sup>Compared to ADV monotherapy group, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05</p></table-wrap-foot></table-wrap></p><p>Typical histology improvements were observed, for example in two cases, No. 1 and No. 2. Necroinflammatory degrees decreased significantly at the end of therapy (Figs.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>b, <xref rid="Fig6" ref-type="fig">6</xref>b) comparing with baseline (Figs.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a, <xref rid="Fig6" ref-type="fig">6</xref>a), respectively.<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Necroinflammation and fibrosis scores of patient No. 1 were significantly improved after 48 weeks therapy (<bold>b</bold>) compared with baseline (<bold>a</bold>) using ADV plus bicyclol</p></caption><graphic xlink:href="12072_2011_9294_Fig5_HTML" id="MO5"/></fig><fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>Necroinflammation and fibrosis scores of patient No. 2 were significantly improved after 48 weeks therapy (<bold>b</bold>) compared with baseline (<bold>a</bold>) using ADV plus bicyclol</p></caption><graphic xlink:href="12072_2011_9294_Fig6_HTML" id="MO6"/></fig></p></sec><sec id="Sec15"><title>Safety profiles</title><p>There were no serious adverse events during the course of this study. In 125 treated patients, 15 had 12.0% adverse events. In 125 patients from the ADV monotherapy group, 18 had 14.4% adverse events. The difference was not statistically significant. All the adverse events were nonspecific, including respiratory infections, lower limb pain, bleeding gums, rashes, diarrhea, insomnia, etc (Table <xref rid="Tab5" ref-type="table">5</xref>). During therapy uncomfortable symptoms were almost relieved after symptomatic treatment. There was no incidence of study drugs being discontinued because of adverse events. No drug-related severe adverse events and laboratory abnormalities were observed. Renal function was checked during treatment, including serum creatinine and blood urea nitrogen. No significant differences were observed for creatinine and blood urea nitrogen levels at baseline and at 48&#x000a0;weeks therapy. <table-wrap id="Tab5"><label>Table&#x000a0;5</label><caption><p>Comparison of adverse events incidence of patients in ADV monotherapy and ADV plus bicyclol combination therapy groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Combination (15/125)</th><th align="left">Monotherapy (18/125)</th></tr></thead><tbody><tr><td align="left">Respiratory infection</td><td align="left">5</td><td align="left">6</td></tr><tr><td align="left">Lower limb pain</td><td align="left">3</td><td align="left">5</td></tr><tr><td align="left">Bleeding gum</td><td align="left">3</td><td align="left">3</td></tr><tr><td align="left">Rashes</td><td align="left">2</td><td align="left">2</td></tr><tr><td align="left">Diarrhea</td><td align="left">1</td><td align="left">1</td></tr><tr><td align="left">Insomnia</td><td align="left">1</td><td align="left">1</td></tr></tbody></table><table-wrap-foot><p>No significant differences were observed in ADV monotherapy comparing with ADV plus bicyclol combination therapy groups</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec16"><title>Discussion</title><p>Oral NUC is easily acceptable by the CHB patients for its convenience and few side effects [<xref ref-type="bibr" rid="CR26">26</xref>]. After a short period of treatment, most of the patients were able to achieve undetectable HBV DNA. Although HBV DNA response is usually satisfied, histological improvement is quite limited [<xref ref-type="bibr" rid="CR27">27</xref>]. To optimize histological improvement and look for long-term benefits for patients with CHB, de novo combination therapy is one of the options. ADV is widely used in the clinical treatment of CHB patients. Domestic and foreign clinical trials showed that it decreased the serum HBV DNA and ALT levels, improved liver histology in both HBeAg-positive and HBeAg-negative patients with CHB, and resulted in HBeAg seroconversion in HBeAg-positive patients. Treatment has been found to be safe and well tolerated, with a low incidence of adverse events [<xref ref-type="bibr" rid="CR28">28</xref>]. But ADV is usually used as monotherapy. Bicyclol is a liver protectant drug for patients with various liver diseases including viral hepatitis, drug-induced liver injuries, alcohol liver diseases, and autoimmune liver diseases in many countries [<xref ref-type="bibr" rid="CR29">29</xref>]. Clinical studies demonstrated that bicyclol treatment for a year could achieve significant improvement in liver histology for various kinds of liver diseases [<xref ref-type="bibr" rid="CR30">30</xref>]. For both ADV and bicyclol, monotherapy only could achieve limited liver histological improvement. It is thus reasonable to explore the combination therapy using ADV plus bicyclol for the treatment of CHB patients.</p><p>Bicyclol is a widely used liver protectant drug in China and other countries. Clinical trial was performed by double blind, randomized, and positive control or placebo method in multi-medical centers in China, using bicyclol 25&#x000a0;mg thrice daily for 6&#x000a0;months demonstrating ALT AST normalization in 50% of the patients with chronic viral hepatitis B and C. Eight articles reported the efficacy of the combination therapy of lamivudine plus bicyclol and lamivudine or bicyclol used alone [<xref ref-type="bibr" rid="CR31">31</xref>]. The results are briefly summarized as follows: total of more than 200 CHB patients enrolled in the trials were previously treated with lamivudine, some of them had already developed drug resistance to lamivudine because of YMDD development. The schedule of treatment was lamivudine 100&#x000a0;mg, q.d. plus bicyclol 25 or 50&#x000a0;mg, t.i.d. p.o. for 24 or 48&#x000a0;weeks. In general, at the end of combination therapy of lamivudine plus bicyclol, the effectiveness of anti-HBV DNA and negative of HBeAg were higher than lamivudine or bicyclol used alone, particularly the YMDD mutant, and relapse rate of virus markers was reduced. Two articles reported the therapeutic effect of IFNa-2b alone and in combination with bicyclol in CHB. In general, as compared to INFa-2b treatment alone, the combination of bicyclol with INFa-2b increased the improvement of the abnormal liver function and HBV-DNA negative, and reduced adverse reaction of INFa-2b.</p><p>To use ADV and bicyclol in combination therapy for CHB patient, one concern might be the drug&#x02013;drug interaction, and its effects on treatment and safety profiles. From this trial, we did not observe more side effects in the combination therapy group than in ADV monotherapy group, indicating de novo combination therapy of these two drugs is safe. Because of the complexity of bicyclol function, the influence of the drug on ADV antiviral effect is yet to be elucidated. From the percentages of patients with HBV DNA &#x02264;1,000 log<sub>10</sub> copies/mL, HBeAg loss, and HBeAg seroconversion at the end of therapy, there were no significant differences between monotherapy and combination therapy groups, demonstrating that the addition of liver protectant drug bicyclol to ADV antiviral therapy did not affect the ADV antiviral efficacy. Nevertheless, a significant histological improvement has been confirmed for both monotherapy and combination therapy groups. At the same time, this study clearly revealed that de novo combination of ADV plus bicyclol could achieve even better histological improvement for HBeAg-positive CHB patients.</p><p>The advantage of using de novo combination of ADV and bicyclol could be seen as early as 12&#x000a0;weeks of therapy. From week 12, the rates of ALT and AST normalization for patients with combination therapy were significantly superior to that of patients on monotherapy. In combination with the more significant improvement in liver histology at the end of therapy and the safety profile of this de novo combination therapy, the result of this study convinced us for its value in exploring a better treatment regimen for CHB patients.</p><p>To finally establish a new strategy for patients with CHB, a prolonged treatment and long-term follow-up are needed. The mechanism for potential drug interaction, treatment efficacy, and factors determining the efficacy of this combination therapy await further elucidation. Various combinations with different NUC and liver protectant drugs [<xref ref-type="bibr" rid="CR32">32</xref>] are also the clinical interests in the future. Because of the limited number of cases included in this study, and comparatively short-term treatment, it is required to expand the sample size and extend the treatment duration to have firm conclusion. Optimized treatment course and long-term follow-up after cessation of the treatment are also important in future.</p></sec></body><back><ack><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Custer</surname><given-names>B</given-names></name><name><surname>Sullivan</surname><given-names>SD</given-names></name><name><surname>Hazlet</surname><given-names>TK</given-names></name><etal/></person-group><article-title>Global epidemiology of hepatitis B virus</article-title><source>J Clin Gastroenterol</source><year>2004</year><volume>38</volume><fpage>S158</fpage><lpage>S168</lpage><pub-id pub-id-type="doi">10.1097/00004836-200411003-00008</pub-id><pub-id pub-id-type="pmid">15602165</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendy</surname><given-names>ME</given-names></name><name><surname>Welzel</surname><given-names>T</given-names></name><name><surname>Lesi</surname><given-names>OA</given-names></name><etal/></person-group><article-title>Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa</article-title><source>J Viral Hepat</source><year>2010</year><volume>17</volume><fpage>115</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2893.2009.01168.x</pub-id><pub-id pub-id-type="pmid">19874478</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lok</surname><given-names>AS</given-names></name><name><surname>McMahon</surname><given-names>BJ</given-names></name></person-group><article-title>Chronic hepatitis B</article-title><source>Hepatology</source><year>2007</year><volume>45</volume><fpage>507</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1002/hep.21513</pub-id><pub-id pub-id-type="pmid">17256718</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dan</surname><given-names>YY</given-names></name><name><surname>Aung</surname><given-names>MO</given-names></name><name><surname>Lim</surname><given-names>SG</given-names></name></person-group><article-title>The economics of treating chronic hepatitis B in Asia</article-title><source>Hepatol Int</source><year>2008</year><volume>2</volume><fpage>284</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1007/s12072-008-9049-2</pub-id><pub-id pub-id-type="pmid">19669256</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Gu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis</article-title><source>J Natl Cancer Inst</source><year>2009</year><volume>101</volume><fpage>1066</fpage><lpage>1082</lpage><pub-id pub-id-type="doi">10.1093/jnci/djp180</pub-id><pub-id pub-id-type="pmid">19574418</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sylvan</surname><given-names>SP</given-names></name><name><surname>Hellstrom</surname><given-names>UB</given-names></name></person-group><article-title>Modulation of serum interleukin-18 concentrations and hepatitis B virus DNA levels during interferon therapy in patients with hepatitis B e-antigen-positive chronic hepatitis B</article-title><source>J Interferon Cytokine Res</source><year>2010</year><volume>30</volume><fpage>901</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1089/jir.2010.0042</pub-id><pub-id pub-id-type="pmid">20973680</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolters</surname><given-names>LM</given-names></name><name><surname>Niesters</surname><given-names>HG</given-names></name><name><surname>Man</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Nucleoside analogues for chronic hepatitis B</article-title><source>Eur J Gastroenterol Hepatol</source><year>2001</year><volume>13</volume><fpage>1499</fpage><lpage>1507</lpage><pub-id pub-id-type="doi">10.1097/00042737-200112000-00016</pub-id><pub-id pub-id-type="pmid">11742201</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dakin</surname><given-names>H</given-names></name><name><surname>Bentley</surname><given-names>A</given-names></name><name><surname>Dusheiko</surname><given-names>G</given-names></name></person-group><article-title>Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B</article-title><source>Value Health</source><year>2010</year><volume>13</volume><fpage>922</fpage><lpage>933</lpage><pub-id pub-id-type="doi">10.1111/j.1524-4733.2010.00782.x</pub-id><pub-id pub-id-type="pmid">20825619</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schif</surname><given-names>ER</given-names></name><name><surname>Lai</surname><given-names>CL</given-names></name><name><surname>Hadziyannis</surname><given-names>S</given-names></name><etal/></person-group><article-title>Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre-and post-liver transplantation patients</article-title><source>Hepatology</source><year>2003</year><volume>38</volume><fpage>1419</fpage><lpage>1427</lpage><pub-id pub-id-type="pmid">14647053</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcellin</surname><given-names>P</given-names></name><name><surname>Cadranel</surname><given-names>JF</given-names></name><name><surname>Fontanges</surname><given-names>T</given-names></name><etal/></person-group><article-title>High rate of adefovir&#x02013;lamivudine combination therapy in nucleoside-na&#x000ef;ve patients with chronic hepatitis B in France: results of a national survey in 1730 patients</article-title><source>Eur J Gastroenterol Hepatol</source><year>2010</year><volume>22</volume><fpage>1290</fpage><lpage>1296</lpage><pub-id pub-id-type="doi">10.1097/MEG.0b013e32832fba4f</pub-id><pub-id pub-id-type="pmid">20964259</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Upadhyaya</surname><given-names>N</given-names></name><name><surname>Chang</surname><given-names>R</given-names></name><name><surname>Davis</surname><given-names>C</given-names></name><etal/></person-group><article-title>Chronic hepatitis B: perceptions in Asian American communities and diagnosis and management practices among primary care physicians</article-title><source>Postgrad Med</source><year>2010</year><volume>122</volume><fpage>165</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.3810/pgm.2010.09.2213</pub-id><pub-id pub-id-type="pmid">20861600</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>TT</given-names></name><name><surname>Liaw</surname><given-names>YF</given-names></name><name><surname>Wu</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B</article-title><source>Hepatology</source><year>2010</year><volume>52</volume><fpage>886</fpage><lpage>893</lpage><pub-id pub-id-type="doi">10.1002/hep.23785</pub-id><pub-id pub-id-type="pmid">20683932</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tak</surname><given-names>WY</given-names></name><name><surname>Park</surname><given-names>SY</given-names></name><name><surname>Cho</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy</article-title><source>J Hepatol</source><year>2010</year><volume>53</volume><fpage>261</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2010.03.006</pub-id><pub-id pub-id-type="pmid">20466447</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadziyannis</surname><given-names>SJ</given-names></name><name><surname>Tassopoulos</surname><given-names>NC</given-names></name><name><surname>Heathcote</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>2673</fpage><lpage>2681</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa042957</pub-id><pub-id pub-id-type="pmid">15987916</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcellin</surname><given-names>P</given-names></name><name><surname>Chang</surname><given-names>TT</given-names></name><name><surname>Lim</surname><given-names>SG</given-names></name><etal/></person-group><article-title>Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><fpage>808</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa020681</pub-id><pub-id pub-id-type="pmid">12606735</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Ahn</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B</article-title><source>J Med Virol</source><year>2010</year><volume>82</volume><fpage>1835</fpage><lpage>1842</lpage><pub-id pub-id-type="doi">10.1002/jmv.21898</pub-id><pub-id pub-id-type="pmid">20872709</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freedman</surname><given-names>ND</given-names></name><name><surname>Curto</surname><given-names>TM</given-names></name><name><surname>Morishima</surname><given-names>C</given-names></name><etal/></person-group><article-title>Silymarin use and liver disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial</article-title><source>Aliment Pharmacol Ther</source><year>2011</year><volume>33</volume><fpage>127</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2010.04503.x</pub-id><pub-id pub-id-type="pmid">21083592</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Preparation and evaluation of <italic>N</italic>-caproyl chitosan nanoparticles surface modified with glycyrrhizin for hepatocyte targeting</article-title><source>Drug Dev Ind Pharm</source><year>2009</year><volume>35</volume><fpage>1348</fpage><lpage>1355</lpage><pub-id pub-id-type="doi">10.3109/03639040902939197</pub-id><pub-id pub-id-type="pmid">19832635</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>GT</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>HL</given-names></name><etal/></person-group><article-title>Mechanism of protective action of bicyclol against CCl<sub>4</sub>-induced liver injury in mice</article-title><source>Liver Int</source><year>2005</year><volume>25</volume><fpage>872</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1111/j.1478-3231.2005.01103.x</pub-id><pub-id pub-id-type="pmid">15998439</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Bao XQ, Liu GT. Involvement of HSP70 in the protection of bicyclol on apoptosis of HepG2 cells intoxicated by <sc>d</sc>-galactosamine. J Asian Nat Prod Res 12:313&#x02013;323</mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lou</surname><given-names>XE</given-names></name><name><surname>Xu</surname><given-names>N</given-names></name><name><surname>Yao</surname><given-names>HP</given-names></name><etal/></person-group><article-title>Bicyclol attenuates pro-inflammatory cytokine and chemokine productions in CpG-DNA-stimulated L02 hepatocytes by inhibiting p65-NF-kappaB and p38-MAPK activation</article-title><source>Pharmazie</source><year>2010</year><volume>65</volume><fpage>206</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">20383942</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>YN</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Effect of bicyclol on cisplatin-induced hepatotoxicity in the hepatocarcinoma 22 tumour-bearing mice</article-title><source>Basic Clin Pharmacol Toxicol</source><year>2009</year><volume>104</volume><fpage>300</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1111/j.1742-7843.2008.00343.x</pub-id><pub-id pub-id-type="pmid">19210495</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>XQ</given-names></name><name><surname>Liu</surname><given-names>GT</given-names></name></person-group><article-title>Induction of overexpression of the 27-and 70-kDa heat shock proteins by bicyclol attenuates concanavalin A-induced liver injury through suppression of nuclear factor-kappaB in mice</article-title><source>Mol Pharmacol</source><year>2009</year><volume>75</volume><fpage>1180</fpage><lpage>1188</lpage><pub-id pub-id-type="doi">10.1124/mol.108.053280</pub-id><pub-id pub-id-type="pmid">19188336</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>GT</given-names></name></person-group><article-title>Inhibitory effect of anti-hepatitis drug bicyclol on invasion of human hepatocellular carcinoma MHCC97-H cells with high metastasis potential and its relative mechanisms</article-title><source>J Asian Nat Prod Res</source><year>2009</year><volume>11</volume><fpage>576</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.1080/10286020902942368</pub-id><pub-id pub-id-type="pmid">20183293</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knodell</surname><given-names>RG</given-names></name><name><surname>Ishak</surname><given-names>KG</given-names></name><name><surname>Black</surname><given-names>WC</given-names></name><etal/></person-group><article-title>Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis</article-title><source>Hepatology</source><year>1981</year><volume>1</volume><fpage>431</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1002/hep.1840010511</pub-id><pub-id pub-id-type="pmid">7308988</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westland</surname><given-names>CE</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Delaney</surname><given-names>WE</given-names></name><etal/></person-group><article-title>Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients</article-title><source>J Viral Hepatitis</source><year>2005</year><volume>12</volume><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2893.2005.00578.x</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minde</surname><given-names>Z</given-names></name><name><surname>Yimin</surname><given-names>M</given-names></name><name><surname>Guangbi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg positive chronic hepatitis B</article-title><source>Hepatology</source><year>2006</year><volume>43</volume><fpage>108</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1002/hep.21005</pub-id><pub-id pub-id-type="pmid">16374873</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Park</surname><given-names>DI</given-names></name><etal/></person-group><article-title>Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0&#x000a0;mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy</article-title><source>J Gastroenterol Hepatol</source><year>2006</year><volume>25</volume><fpage>1374</fpage><lpage>1380</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1746.2010.06381.x</pub-id><pub-id pub-id-type="pmid">20659226</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>GT</given-names></name></person-group><article-title>Inhibition of Fas/FasL mRNA expression and TNF-&#x003b1; release in concanavalin A-induced liver injury in mice by bicyclol</article-title><source>World J Gastroenterol</source><year>2004</year><volume>10</volume><fpage>1775</fpage><lpage>1779</lpage><pub-id pub-id-type="pmid">15188504</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>GT</given-names></name></person-group><article-title>Bicyclol: a novel drug for treating chronic viral hepatitis B and C</article-title><source>Med Chem</source><year>2009</year><volume>5</volume><fpage>29</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.2174/157340609787049316</pub-id><pub-id pub-id-type="pmid">19149648</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Geng Tao</given-names></name></person-group><article-title>Bicyclol: A novel drug for treating chronic viral hepatitis B and C</article-title><source>Med Chem</source><year>2009</year><volume>5</volume><fpage>29</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.2174/157340609787049316</pub-id><pub-id pub-id-type="pmid">19149648</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>XQ</given-names></name><name><surname>Liu</surname><given-names>GT</given-names></name></person-group><article-title>Bicyclol protects HepG2 cells against <sc>d</sc>-galactosamine-induced apoptosis through inducing heat shock protein 27 and mitochondria associated pathway</article-title><source>Acta Pharmacol Sin</source><year>2010</year><volume>31</volume><fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1038/aps.2009.194</pub-id><pub-id pub-id-type="pmid">20139905</pub-id></mixed-citation></ref></ref-list></back></article>